RxDoctor Payments Data

Denise Cubero-Walker, MD

Internal Medicine · Lexington, SCNPI 1679586879

Payments from drug & device makers

$1,659in general payments, 2019–2025

Across 103 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$243
  • AstraZeneca$133
  • Pfizer$128
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$91
  • Abbott$84
  • AbbVie$82
  • plus $899 from 25 others

What the payments were for

  • Food & beverage$1,659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,659 in reported general payments places this provider in the 70th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$167,034
Medicare patients
328
Services billed
3,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$112,060
MounjaroTirzepatide39$58,318
XifaxanRifaximin18$57,030
JardianceEmpagliflozin33$33,933
FarxigaDapagliflozin Propanediol34$31,896
TrulicityDulaglutide19$31,454
EliquisApixaban25$26,155
JanuviaSitagliptin Phosphate16$20,180
MyrbetriqMirabegron22$18,710
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,016
Breo ElliptaFluticasone/Vilanterol21$15,581
Tresiba Flextouch U-200Insulin Degludec12$13,420
TradjentaLinagliptin23$11,877
Atorvastatin Calcium333$4,708
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$4,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$243$112,06070 claims
Lilly USA, LLCMounjaro, Trulicity$57$89,77258 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$91$57,03018 claims
Boehringer IngelheimJardiance, Tradjenta$11$45,81056 claims
AstraZenecaFarxiga$133$31,89634 claims
GSKTrelegy Ellipta, Breo Ellipta$30$31,59745 claims
PfizerEliquis, Premarin$128$29,92240 claims
Astellas Pharma US IncMyrbetriq$48$18,71022 claims
AbbVieSynthroid$82$3,69966 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Lexington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →